Pharmabiz6h
Anixa Biosciences begins patient dosing in third cohort in ongoing phase 1 trial of novel CAR-T therapy for recurrent ovarian cancer
Anixa Biosciences begins patient dosing in third cohort in ongoing phase 1 trial of novel CAR-T therapy for recurrent ovarian cancer: San Jose, California Wednesday, November 20, ...
Pharmabiz7h
NIH-developed AI algorithm matches potential volunteers to clinical trials
NIH-developed AI algorithm matches potential volunteers to clinical trials: Bethesda, Maryland Wednesday, November 20, 2024, 17:00 Hrs [IST] Researchers from the National Institut ...
Pharmabiz8h
TAHO Pharma begins patient dosing in US phase III trial of antithrombotic oral dissolving film, TAH3311
TAHO Pharma begins patient dosing in US phase III trial of antithrombotic oral dissolving film, TAH3311: Taipei Wednesday, November 20, 2024, 16:00 Hrs [IST] TAHO Pharmaceuticals ...
Pharmabiz10h
UK MHRA grants marketing authorization to sparsentan to treat adult patients with primary immunoglobulin A nephropathy
UK MHRA grants marketing authorization to sparsentan to treat adult patients with primary immunoglobulin A nephropathy: United Kingdom Wednesday, November 20, 2024, 14:00 Hrs [IST ...
Pharmabiz9h
Cytokinetics, Bayer enter collaboration and licensing pact to develop & commercialize aficamten in Japan
Cytokinetics, Bayer enter collaboration and licensing pact to develop & commercialize aficamten in Japan: South San Francisco, California Wednesday, November 20, 2024, 15:00 Hrs [ ...
Pharmabiz9h
Sightsavers India with AbbVie India hosted the 4th state-level consultation on ‘Prevention of Visual Impairment Caused by Glaucoma’
Sightsavers India and AbbVie India, in their ongoing collaborative campaign, hosted the fourth state-level consultation on the ‘Prevention of Visual Impairment Caused by Glaucoma.’ Glaucoma, a leading ...
Pharmabiz9h
Sova Health launches Sova X, a personalized gut health solution based on each individual's microbiome
Sova Health launches Sova X, a personalized gut health solution based on each individual's microbiome: Our Bureau, Bengaluru Wednesday, November 20, 2024, 14:30 Hrs [IST] Gut-heal ...
Pharmabiz9h
Granules India appoints Ovais Sarmad as advisor to guide on Sustainability and Climate Strategy
Granules India appoints Ovais Sarmad as advisor to guide on Sustainability and Climate Strategy: Our Bureau, Bengaluru Wednesday, November 20, 2024, 14:40 Hrs [IST] Granules India ...
Pharmabiz12h
Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets
Biosion inks exclusive, global license pact with Aclaris Therapeutics on two potential first-in-class and best-in-class immunology assets: Newark, Delaware Wednesday, November 20, ...
Pharmabiz11h
India‘s medical tourism accounts for 8% global market share as international patients convinced on quality care and expertise
India‘s medical tourism accounts for 8% global market share as international patients convinced on quality care and expertise: Our Bureau, Bengaluru Wednesday, November 20, 2024 ...
Pharmabiz14h
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...
Pharmabiz12h
AVPN & Bayer Foundation unveil US$ 5 million “Climate x Health: Lighthouse for Asia” Fund to protect community health
AVPN & Bayer Foundation unveil US$ 5 million “Climate x Health: Lighthouse for Asia” Fund to protect community health: Our Bureau, Bengaluru Wednesday, November 20, 2024, 11:1 ...